Trial reportEuropean journal of applied physiology2012
Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation.
Trial report in European journal of applied physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Testosterone supplementation and body composition: results from a meta-analysis of observational studies.Journal of endocrinological investigation · 2016Pooled it
- Effects of elastic band resistance training and nutritional supplementation on muscle quality and circulating muscle growth and degradation factors of institutionalized elderly women: the Vienna Active Ageing Study (VAAS).European journal of applied physiology · 2016Trial
- Treatment of sporadic inclusion body myositis with bimagrumab.Neurology · 2014Trial
- Trial
- Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.The Lancet. Oncology · 2013Trial
- Increased 1-year mortality rates after hip fracture surgery in geriatric patients with skeletal muscle atrophy: a propensity score-matched study.BMC geriatrics · 2026Article
- Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy.Neurology. Genetics · 2025Article
- "Bioelectrical impedance analysis in managing sarcopenic obesity in NAFLD".Obesity science & practice · 2021Review
- The Impact of SARS-CoV-2 Infection on Fertility and Female and Male Reproductive Systems.Journal of clinical medicine · 2021Review
- Combined effects of growth hormone and testosterone replacement treatment in heart failure.ESC heart failure · 2019Article
- Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives.Current obesity reports · 2019Review
- Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies.Nature reviews. Endocrinology · 2018Review
- Perioperative Testosterone Supplementation Increases Lean Mass in Healthy Men Undergoing Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial.Orthopaedic journal of sports medicine · 2017Article
- Sarcopenia.Best practice & research. Clinical rheumatology · 2017Review
- Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.The lancet. Diabetes & endocrinology · 2014Review
- The role of androgens and estrogens on healthy aging and longevity.The journals of gerontology. Series A, Biological sciences and medical sciences · 2012Review
- Androgen effects on skeletal muscle: implications for the development and management of frailty.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
We hypothesized that treatment with testosterone (T) and recombinant human growth hormone (rhGH) would increase lean mass (LM) and muscle strength proportionally and an in a linear manner over 16 weeks. This was a multicenter, randomized, controlled, double-masked investigation of T and rhGH supplementation in older (71 ± 4 years) community-dwelling men. Participants received transdermal T at either 5 or 10 g/day as well as rhGH at 0, 3.0 or 5.0 μg/kg/day for 16 weeks. Body composition was determined by dual-energy X-ray absorptiometry (DEXA) and muscle performance by composite one-repetition maximum (1-RM) strength and strength per unit of lean mass (muscle quality, MQ) for five major muscle groups (upper and lower body) at baseline, week 8 and 17. The average change in total LM at study week 8 compared with baseline was 1.50 ± 1.54 kg (P < 0.0001) in the T only group and 2.64 ± 1.7 (P < 0.0001) in the T + rhGH group and at week 17 was 1.46 ± 1.48 kg (P < 0.0001) in the T only group and 2.14 ± 1.96 kg (P < 0.0001) in the T + rhGH group. 1-RM strength improved modestly in both groups combined (12.0 ± 23.9%, P < 0.0001) at week 8 but at week 17 these changes were twofold greater (24.7 ± 31.0%, P < 0.0001). MQ did not significantly change from baseline to week 8 but increased for the entire cohort, T only, and T + rhGH groups by week 17 (P < 0.001). Despite sizeable increases in LM measurements at week 8, tests of muscle performance did not show substantive improvements at this time point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.